18F-FDG PET/CT显像监测胃癌术后复发转移的价值

Objective PET with 18F-fluorodeoxyglucose (FDG) has been used to beth detect and stage a variety of malignancies. The aim of this retrospective study was to evaluate the clinical value of 18F-FDG PET/CT for recurrence and metastasis in gastric carcinoma patients after total gastrectomy. Methods A total of 45 gastric carcinoma patients who underwent total gastrectomy were included. PET/CT scans were obtained for restaging. The " gold standard" of 18F-FDG PET/CT diagnostic accuracy was based on either histopathology or clinical follow-up. By using the t-test from SPSS 11.5, the cut-off of maximum standard-ized uptake values (SUVmax) from 18F-FDG to differentiate benign from malignant lesion at stomach were determined and calculated. Results (1) Of the 45 patients, 22 were suspicion recurrent lesion at stomach. Of the 22 patients, 12 were confirmed to have recurrent lesions. The diagnostic accuracy were 100.0% (12/ 12) for sensitivity, 70.0% (7/10) for specificity, and 86.4% (19/22) for accuracy, respectively. A higher SUVmax in malignant than benign lesion was noted (6.27 ± 3.42 vs 3.92 ± 2.24), though not reached to the significance (t = 1. 862, P > 0.05). (2) For extra-gastric lesion detection, the sensitivity, specificity, and accuracy for region lymph nodes were 78.9% (15/19), 92.3% (24/26), and 86.7% (39/ 45), for peritoneal spreading were 6/9, 97.2% (35/36), 91. 1% (41/45), and for distant sites were 86.7%(13/15), 93.3% (28/30), 91.1% (41/45). (3) False positive were found in eight sites. All were either inflammatory or physiological uptake at intestine. False negative were found in nine sites. Either due to small in size (less than 1.0 cm in diameter), well differentiation of the tumor cell or with a nature of signet ring. Conclusion 18F-FDG PET/CT had a potential to detect local, regional, and distant metastasis in gastric cancer.     

18F-FDG PET/CT显像监测胃癌术后复发转移的价值

Objective PET with 18F-fluorodeoxyglucose (FDG) has been used to beth detect and stage a variety of malignancies. The aim of this retrospective study was to evaluate the clinical value of 18F-FDG PET/CT for recurrence and metastasis in gastric carcinoma patients after total gastrectomy. Methods A total of 45 gastric carcinoma patients who underwent total gastrectomy were included. PET/CT scans were obtained for restaging. The " gold standard" of 18F-FDG PET/CT diagnostic accuracy was based on either histopathology or clinical follow-up. By using the t-test from SPSS 11.5, the cut-off of maximum standard-ized uptake values (SUVmax) from 18F-FDG to differentiate benign from malignant lesion at stomach were determined and calculated. Results (1) Of the 45 patients, 22 were suspicion recurrent lesion at stomach. Of the 22 patients, 12 were confirmed to have recurrent lesions. The diagnostic accuracy were 100.0% (12/ 12) for sensitivity, 70.0% (7/10) for specificity, and 86.4% (19/22) for accuracy, respectively. A higher SUVmax in malignant than benign lesion was noted (6.27 ± 3.42 vs 3.92 ± 2.24), though not reached to the significance (t = 1. 862, P > 0.05). (2) For extra-gastric lesion detection, the sensitivity, specificity, and accuracy for region lymph nodes were 78.9% (15/19), 92.3% (24/26), and 86.7% (39/ 45), for peritoneal spreading were 6/9, 97.2% (35/36), 91. 1% (41/45), and for distant sites were 86.7%(13/15), 93.3% (28/30), 91.1% (41/45). (3) False positive were found in eight sites. All were either inflammatory or physiological uptake at intestine. False negative were found in nine sites. Either due to small in size (less than 1.0 cm in diameter), well differentiation of the tumor cell or with a nature of signet ring. Conclusion 18F-FDG PET/CT had a potential to detect local, regional, and distant metastasis in gastric cancer.     

18F-FDG PET/CT显像监测胃癌术后复发转移的价值

Objective PET with 18F-fluorodeoxyglucose (FDG) has been used to beth detect and stage a variety of malignancies. The aim of this retrospective study was to evaluate the clinical value of 18F-FDG PET/CT for recurrence and metastasis in gastric carcinoma patients after total gastrectomy. Methods A total of 45 gastric carcinoma patients who underwent total gastrectomy were included. PET/CT scans were obtained for restaging. The " gold standard" of 18F-FDG PET/CT diagnostic accuracy was based on either histopathology or clinical follow-up. By using the t-test from SPSS 11.5, the cut-off of maximum standard-ized uptake values (SUVmax) from 18F-FDG to differentiate benign from malignant lesion at stomach were determined and calculated. Results (1) Of the 45 patients, 22 were suspicion recurrent lesion at stomach. Of the 22 patients, 12 were confirmed to have recurrent lesions. The diagnostic accuracy were 100.0% (12/ 12) for sensitivity, 70.0% (7/10) for specificity, and 86.4% (19/22) for accuracy, respectively. A higher SUVmax in malignant than benign lesion was noted (6.27 ± 3.42 vs 3.92 ± 2.24), though not reached to the significance (t = 1. 862, P > 0.05). (2) For extra-gastric lesion detection, the sensitivity, specificity, and accuracy for region lymph nodes were 78.9% (15/19), 92.3% (24/26), and 86.7% (39/ 45), for peritoneal spreading were 6/9, 97.2% (35/36), 91. 1% (41/45), and for distant sites were 86.7%(13/15), 93.3% (28/30), 91.1% (41/45). (3) False positive were found in eight sites. All were either inflammatory or physiological uptake at intestine. False negative were found in nine sites. Either due to small in size (less than 1.0 cm in diameter), well differentiation of the tumor cell or with a nature of signet ring. Conclusion 18F-FDG PET/CT had a potential to detect local, regional, and distant metastasis in gastric cancer.     

18F-FDG PET/CT显像监测胃癌术后复发转移的价值

Objective PET with 18F-fluorodeoxyglucose (FDG) has been used to beth detect and stage a variety of malignancies. The aim of this retrospective study was to evaluate the clinical value of 18F-FDG PET/CT for recurrence and metastasis in gastric carcinoma patients after total gastrectomy. Methods A total of 45 gastric carcinoma patients who underwent total gastrectomy were included. PET/CT scans were obtained for restaging. The " gold standard" of 18F-FDG PET/CT diagnostic accuracy was based on either histopathology or clinical follow-up. By using the t-test from SPSS 11.5, the cut-off of maximum standard-ized uptake values (SUVmax) from 18F-FDG to differentiate benign from malignant lesion at stomach were determined and calculated. Results (1) Of the 45 patients, 22 were suspicion recurrent lesion at stomach. Of the 22 patients, 12 were confirmed to have recurrent lesions. The diagnostic accuracy were 100.0% (12/ 12) for sensitivity, 70.0% (7/10) for specificity, and 86.4% (19/22) for accuracy, respectively. A higher SUVmax in malignant than benign lesion was noted (6.27 ± 3.42 vs 3.92 ± 2.24), though not reached to the significance (t = 1. 862, P > 0.05). (2) For extra-gastric lesion detection, the sensitivity, specificity, and accuracy for region lymph nodes were 78.9% (15/19), 92.3% (24/26), and 86.7% (39/ 45), for peritoneal spreading were 6/9, 97.2% (35/36), 91. 1% (41/45), and for distant sites were 86.7%(13/15), 93.3% (28/30), 91.1% (41/45). (3) False positive were found in eight sites. All were either inflammatory or physiological uptake at intestine. False negative were found in nine sites. Either due to small in size (less than 1.0 cm in diameter), well differentiation of the tumor cell or with a nature of signet ring. Conclusion 18F-FDG PET/CT had a potential to detect local, regional, and distant metastasis in gastric cancer.     

18F-FDG PET/CT显像监测胃癌术后复发转移的价值

Objective PET with 18F-fluorodeoxyglucose (FDG) has been used to beth detect and stage a variety of malignancies. The aim of this retrospective study was to evaluate the clinical value of 18F-FDG PET/CT for recurrence and metastasis in gastric carcinoma patients after total gastrectomy. Methods A total of 45 gastric carcinoma patients who underwent total gastrectomy were included. PET/CT scans were obtained for restaging. The " gold standard" of 18F-FDG PET/CT diagnostic accuracy was based on either histopathology or clinical follow-up. By using the t-test from SPSS 11.5, the cut-off of maximum standard-ized uptake values (SUVmax) from 18F-FDG to differentiate benign from malignant lesion at stomach were determined and calculated. Results (1) Of the 45 patients, 22 were suspicion recurrent lesion at stomach. Of the 22 patients, 12 were confirmed to have recurrent lesions. The diagnostic accuracy were 100.0% (12/ 12) for sensitivity, 70.0% (7/10) for specificity, and 86.4% (19/22) for accuracy, respectively. A higher SUVmax in malignant than benign lesion was noted (6.27 ± 3.42 vs 3.92 ± 2.24), though not reached to the significance (t = 1. 862, P > 0.05). (2) For extra-gastric lesion detection, the sensitivity, specificity, and accuracy for region lymph nodes were 78.9% (15/19), 92.3% (24/26), and 86.7% (39/ 45), for peritoneal spreading were 6/9, 97.2% (35/36), 91. 1% (41/45), and for distant sites were 86.7%(13/15), 93.3% (28/30), 91.1% (41/45). (3) False positive were found in eight sites. All were either inflammatory or physiological uptake at intestine. False negative were found in nine sites. Either due to small in size (less than 1.0 cm in diameter), well differentiation of the tumor cell or with a nature of signet ring. Conclusion 18F-FDG PET/CT had a potential to detect local, regional, and distant metastasis in gastric cancer.     

18F-FDG PET/CT显像监测胃癌术后复发转移的价值

Objective PET with 18F-fluorodeoxyglucose (FDG) has been used to beth detect and stage a variety of malignancies. The aim of this retrospective study was to evaluate the clinical value of 18F-FDG PET/CT for recurrence and metastasis in gastric carcinoma patients after total gastrectomy. Methods A total of 45 gastric carcinoma patients who underwent total gastrectomy were included. PET/CT scans were obtained for restaging. The " gold standard" of 18F-FDG PET/CT diagnostic accuracy was based on either histopathology or clinical follow-up. By using the t-test from SPSS 11.5, the cut-off of maximum standard-ized uptake values (SUVmax) from 18F-FDG to differentiate benign from malignant lesion at stomach were determined and calculated. Results (1) Of the 45 patients, 22 were suspicion recurrent lesion at stomach. Of the 22 patients, 12 were confirmed to have recurrent lesions. The diagnostic accuracy were 100.0% (12/ 12) for sensitivity, 70.0% (7/10) for specificity, and 86.4% (19/22) for accuracy, respectively. A higher SUVmax in malignant than benign lesion was noted (6.27 ± 3.42 vs 3.92 ± 2.24), though not reached to the significance (t = 1. 862, P > 0.05). (2) For extra-gastric lesion detection, the sensitivity, specificity, and accuracy for region lymph nodes were 78.9% (15/19), 92.3% (24/26), and 86.7% (39/ 45), for peritoneal spreading were 6/9, 97.2% (35/36), 91. 1% (41/45), and for distant sites were 86.7%(13/15), 93.3% (28/30), 91.1% (41/45). (3) False positive were found in eight sites. All were either inflammatory or physiological uptake at intestine. False negative were found in nine sites. Either due to small in size (less than 1.0 cm in diameter), well differentiation of the tumor cell or with a nature of signet ring. Conclusion 18F-FDG PET/CT had a potential to detect local, regional, and distant metastasis in gastric cancer.     

18F-FDG PET/CT显像监测胃癌术后复发转移的价值

Objective PET with 18F-fluorodeoxyglucose (FDG) has been used to beth detect and stage a variety of malignancies. The aim of this retrospective study was to evaluate the clinical value of 18F-FDG PET/CT for recurrence and metastasis in gastric carcinoma patients after total gastrectomy. Methods A total of 45 gastric carcinoma patients who underwent total gastrectomy were included. PET/CT scans were obtained for restaging. The " gold standard" of 18F-FDG PET/CT diagnostic accuracy was based on either histopathology or clinical follow-up. By using the t-test from SPSS 11.5, the cut-off of maximum standard-ized uptake values (SUVmax) from 18F-FDG to differentiate benign from malignant lesion at stomach were determined and calculated. Results (1) Of the 45 patients, 22 were suspicion recurrent lesion at stomach. Of the 22 patients, 12 were confirmed to have recurrent lesions. The diagnostic accuracy were 100.0% (12/ 12) for sensitivity, 70.0% (7/10) for specificity, and 86.4% (19/22) for accuracy, respectively. A higher SUVmax in malignant than benign lesion was noted (6.27 ± 3.42 vs 3.92 ± 2.24), though not reached to the significance (t = 1. 862, P > 0.05). (2) For extra-gastric lesion detection, the sensitivity, specificity, and accuracy for region lymph nodes were 78.9% (15/19), 92.3% (24/26), and 86.7% (39/ 45), for peritoneal spreading were 6/9, 97.2% (35/36), 91. 1% (41/45), and for distant sites were 86.7%(13/15), 93.3% (28/30), 91.1% (41/45). (3) False positive were found in eight sites. All were either inflammatory or physiological uptake at intestine. False negative were found in nine sites. Either due to small in size (less than 1.0 cm in diameter), well differentiation of the tumor cell or with a nature of signet ring. Conclusion 18F-FDG PET/CT had a potential to detect local, regional, and distant metastasis in gastric cancer.     

18F-FDG PET/CT显像监测胃癌术后复发转移的价值

Objective PET with 18F-fluorodeoxyglucose (FDG) has been used to beth detect and stage a variety of malignancies. The aim of this retrospective study was to evaluate the clinical value of 18F-FDG PET/CT for recurrence and metastasis in gastric carcinoma patients after total gastrectomy. Methods A total of 45 gastric carcinoma patients who underwent total gastrectomy were included. PET/CT scans were obtained for restaging. The " gold standard" of 18F-FDG PET/CT diagnostic accuracy was based on either histopathology or clinical follow-up. By using the t-test from SPSS 11.5, the cut-off of maximum standard-ized uptake values (SUVmax) from 18F-FDG to differentiate benign from malignant lesion at stomach were determined and calculated. Results (1) Of the 45 patients, 22 were suspicion recurrent lesion at stomach. Of the 22 patients, 12 were confirmed to have recurrent lesions. The diagnostic accuracy were 100.0% (12/ 12) for sensitivity, 70.0% (7/10) for specificity, and 86.4% (19/22) for accuracy, respectively. A higher SUVmax in malignant than benign lesion was noted (6.27 ± 3.42 vs 3.92 ± 2.24), though not reached to the significance (t = 1. 862, P > 0.05). (2) For extra-gastric lesion detection, the sensitivity, specificity, and accuracy for region lymph nodes were 78.9% (15/19), 92.3% (24/26), and 86.7% (39/ 45), for peritoneal spreading were 6/9, 97.2% (35/36), 91. 1% (41/45), and for distant sites were 86.7%(13/15), 93.3% (28/30), 91.1% (41/45). (3) False positive were found in eight sites. All were either inflammatory or physiological uptake at intestine. False negative were found in nine sites. Either due to small in size (less than 1.0 cm in diameter), well differentiation of the tumor cell or with a nature of signet ring. Conclusion 18F-FDG PET/CT had a potential to detect local, regional, and distant metastasis in gastric cancer.     

18F-FDG PET/CT显像监测胃癌术后复发转移的价值

Objective PET with 18F-fluorodeoxyglucose (FDG) has been used to beth detect and stage a variety of malignancies. The aim of this retrospective study was to evaluate the clinical value of 18F-FDG PET/CT for recurrence and metastasis in gastric carcinoma patients after total gastrectomy. Methods A total of 45 gastric carcinoma patients who underwent total gastrectomy were included. PET/CT scans were obtained for restaging. The " gold standard" of 18F-FDG PET/CT diagnostic accuracy was based on either histopathology or clinical follow-up. By using the t-test from SPSS 11.5, the cut-off of maximum standard-ized uptake values (SUVmax) from 18F-FDG to differentiate benign from malignant lesion at stomach were determined and calculated. Results (1) Of the 45 patients, 22 were suspicion recurrent lesion at stomach. Of the 22 patients, 12 were confirmed to have recurrent lesions. The diagnostic accuracy were 100.0% (12/ 12) for sensitivity, 70.0% (7/10) for specificity, and 86.4% (19/22) for accuracy, respectively. A higher SUVmax in malignant than benign lesion was noted (6.27 ± 3.42 vs 3.92 ± 2.24), though not reached to the significance (t = 1. 862, P > 0.05). (2) For extra-gastric lesion detection, the sensitivity, specificity, and accuracy for region lymph nodes were 78.9% (15/19), 92.3% (24/26), and 86.7% (39/ 45), for peritoneal spreading were 6/9, 97.2% (35/36), 91. 1% (41/45), and for distant sites were 86.7%(13/15), 93.3% (28/30), 91.1% (41/45). (3) False positive were found in eight sites. All were either inflammatory or physiological uptake at intestine. False negative were found in nine sites. Either due to small in size (less than 1.0 cm in diameter), well differentiation of the tumor cell or with a nature of signet ring. Conclusion 18F-FDG PET/CT had a potential to detect local, regional, and distant metastasis in gastric cancer.     

18F-FDG PET/CT显像监测胃癌术后复发转移的价值

Objective PET with 18F-fluorodeoxyglucose (FDG) has been used to beth detect and stage a variety of malignancies. The aim of this retrospective study was to evaluate the clinical value of 18F-FDG PET/CT for recurrence and metastasis in gastric carcinoma patients after total gastrectomy. Methods A total of 45 gastric carcinoma patients who underwent total gastrectomy were included. PET/CT scans were obtained for restaging. The " gold standard" of 18F-FDG PET/CT diagnostic accuracy was based on either histopathology or clinical follow-up. By using the t-test from SPSS 11.5, the cut-off of maximum standard-ized uptake values (SUVmax) from 18F-FDG to differentiate benign from malignant lesion at stomach were determined and calculated. Results (1) Of the 45 patients, 22 were suspicion recurrent lesion at stomach. Of the 22 patients, 12 were confirmed to have recurrent lesions. The diagnostic accuracy were 100.0% (12/ 12) for sensitivity, 70.0% (7/10) for specificity, and 86.4% (19/22) for accuracy, respectively. A higher SUVmax in malignant than benign lesion was noted (6.27 ± 3.42 vs 3.92 ± 2.24), though not reached to the significance (t = 1. 862, P > 0.05). (2) For extra-gastric lesion detection, the sensitivity, specificity, and accuracy for region lymph nodes were 78.9% (15/19), 92.3% (24/26), and 86.7% (39/ 45), for peritoneal spreading were 6/9, 97.2% (35/36), 91. 1% (41/45), and for distant sites were 86.7%(13/15), 93.3% (28/30), 91.1% (41/45). (3) False positive were found in eight sites. All were either inflammatory or physiological uptake at intestine. False negative were found in nine sites. Either due to small in size (less than 1.0 cm in diameter), well differentiation of the tumor cell or with a nature of signet ring. Conclusion 18F-FDG PET/CT had a potential to detect local, regional, and distant metastasis in gastric cancer.     

^18F-FDG PET／CT显像监测胃癌术后复发转移的价值

目的评价^18F-脱氧葡萄糖（FDG）PET／CT监测胃癌术后复发及转移的临床价值。方法回顾性分析胃癌术后临床疑复发或转移而行^18F-FDG PET／CT检查的45例患者临床资料,根据细胞学、病理或随访结果分析PET／CT检查结果,计算残胃及转移灶最大标准摄取值（SUVmax）。采用SPSS11．5软件进行数据处理,SUVmax两样本均数比较采用t检验。结果（1）45例中22例临床疑残胃复发,12例患者最终确定残胃复发,^18F-FDG PET／CT诊断残胃复发的灵敏度、特异性及准确性分别为100．0％（12／12）、70．0％（7／10）和86．4％（19／22）,12例复发病灶SUVmax为6．27±3．42（其中2例低分化腺癌的SUVmax较低,分别为2．5和3．3）,另10例无复发的残胃SUVmax为3．92±2．24（其中3例吻合口炎性病灶局部SUVmax较高,分别为8．3,5．2和6．3）,差异无统计学意义（t=1．862,P〉0．05）。（2）对残胃以外转移灶的检出：PET／CT灵敏度、特异性、准确性在区域淋巴结转移中分别为78．9％（15／19）、92．3％（24／26）和86．7％（39／45）,在腹膜转移中分别为6／9、97．2％（35／36）和91．1％（41／45）,在远处转移中分别为86．7％（13／15）、93．3％（28／30）和91．1％（41／45）。（3）PET／CT假阳性8处为炎性或肠管摄取,假阴性9处多为直径〈1．0cm的转移灶和低分化腺癌及印戒细胞癌的转移灶。结论^18F-FDG PET／CT虽然检测胃癌术后区域淋巴结和腹膜转移的灵敏度较低,但仍是监测其术后复发转移的有效手段。     

18F-FDG PET/CT显像对脊柱单发转移瘤的诊断价值

目的 评价18F-FDG PET/CT显像对脊柱单发转移瘤的诊断效能及优势.方法 回顾性分析67例[男41例,女26例,年龄40～83(61.5 ±10.2)岁]有恶性肿瘤病史且经局部CT和(或)MRI检查发现单个椎体病变,疑为骨转移瘤患者的资料.患者均行PET/CT显像,既往未行MRI检查者于PET/CT检查后1周内行病变椎体MRI检查.脊柱单发病灶以病理学诊断或6个月以上影像学及临床随访作为最终诊断依据,将PET/CT融合图像与单纯PET、CT及MRI图像分别对比,评价PET/CT显像对脊柱单发转移瘤的诊断效能及优势.对数据行x2检验.结果 PET/CT显像诊断脊柱单发转移瘤的灵敏度为96.3％(52/54),特异性为84.6％ (11/13),阳性预测值为96.3％(52/54),阴性预测值为84.6％ (11/13),准确性为94.0％(63/67).灵敏度、阴性预测值及准确性与PET[81.5％ (44/54)、44.4％ (8/18)、77.6％(52/67)]相比差异均有统计学意义(x2值分别为6.000、5.134、7.421,均P＜0.05);灵敏度、特异性、阴性预测值、准确性与CT[79.6％(43/54)、53.8％ (7/13)、38.9％(7/18)、74.6％(50/67)]相比差异有统计学意义(,值分别为7.083、4.248、6.482、9.543,均P＜0.05);准确性与MRI[80.6％ (54/67)]相比差异有统计学意义(x2=5.457,P＜0.05).结论 PET/CT对脊柱单发转移瘤有较高的诊断效能及优势.PET/CT准确性高于MRI,当在MRI怀疑脊柱单发转移难以明确性质时,可以通过PET/CT提高诊断准确性.     

PET/CT与增强CT检测乳腺癌及其腋淋巴结转移的对照研究

目的探讨^18F-脱氧葡萄糖（FDG）PET／CT显像与螺旋CT增强扫描检测乳腺癌及其腋淋巴结转移的临床价值。方法27例乳腺肿块患者于同日行^18F—FDG PET／CT显像与CT增强扫描。患者俯卧于乳腺专用泡沫垫上接受检查，前者图像由3位核医学科医师采用目测法结合半定量法进行诊断，后者图像由3位影像科医师分析诊断；最后与病理检查结果对照。结果27例患者PET／CT与增强CT均发现31个乳腺肿块，病理检查证实其中21个为乳腺癌，10个为良性病变；发现腋淋巴结91个，共有66个转移（1例有双侧腋淋巴结转移）；PET／CT显像检测乳腺癌原发灶的灵敏度为80．95％，特异性为90％，阳性预测值为94．44％；检测淋巴结转移的灵敏度为89．39％，特异性为88％，阳性预测值为95．16％。增强CT检测乳腺癌原发灶的灵敏度为90．48％，特异性为60％，阳性预测值为82．61％；检测淋巴结转移的灵敏度为86．36％，特异性为52％，阳性预测值为82．61％。^18F—FDG PET／CT和增强CT对腋淋巴结状态的诊断与病理检查结果的列联系数分别为0．64和0．37；两者对乳腺癌及其腋淋巴结转移的诊断特异性差异有显著性（P〈0．05）；对直径〈2cm的病灶，^18F—FDG PET／CT诊断准确性明显高于增强CT（P〈0．05）。结论^18F—FDG PET／CT对诊断乳腺癌及其腋淋巴结转移的特异性均高于增强CT。     

^18F-FDG PET/CT对可疑复发性宫颈癌的临床价值

目的 探讨^18F-FDG PET/CT在可疑复发性宫颈癌临床诊疗中的价值.方法 回顾性分析51例宫颈癌根治后随访期间临床可疑复发的患者,记录患者的治疗资料、可疑复发表现、18F-FDG PET/CT显像结果、同期常规影像检查结果、病理及临床随访结果、PET/CT结果对临床诊疗的影响.结果 PET/CT诊断宫颈癌复发43例,最终经病理检查及临床随访证实复发性宫颈癌40例,盆腔脓肿2例,放射性肠炎1例;PET/CT未见恶性征象8例,病理检查及临床随访均未见异常.PET/CT诊断复发性宫颈癌灵敏度为100.00%（40/40）,特异性为72.73%（8/11）,准确性为94.12%（48/51）.PET/CT指导制订临床诊疗及随访计划34例,改变治疗计划7例.与其他影像检查相比,PET/CT可发现更多的病灶.结论^18F-FDG PET/CT能有效诊断复发性宫颈癌,指导临床诊疗.     

^18F-FDGPET／CT多次显像在监测和预测非小细胞肺癌术后复发和转移中的价值

目的探讨^18F-FDGPET／CT多次显像在监测和预测NSCLC术后复发和转移中的价值。方法NSCLC患者85例（男64例,女21例;平均年龄58．0岁）,分别于术前1周内和术后3个月接受多次全身^18F—FDGPET／CT显像。肿瘤复发和转移的诊断经病理学确诊或经多种影像学综合诊断并经临床随访证实。计算^18F—FDGPET／CT显像的诊断效能,统计学分析采用疋。检验和两独立样本t检验。结果85例患者中,肿瘤复发和转移43例,无复发和转移42例。PET／CT在半年内检出率为9.3％（4／43）,1年内为30．2％（13／43）,2年内为76．7％（33／43）,2年以上为97．7％（42／43）,未检出2。3％（1／43）。18F-FDGPET／CT对NSCLC复发和转移的诊断灵敏度、特异性、准确性分别为97．7％（42／43）、95．2％（40／42）和96．5％（82／85）。术前肿瘤分期、原发灶大小和原发灶SUVmax是2年内肿瘤复发和转移的影响因素似。12．360,t=3．281和2．465,均P〈0．05）,而性别、年龄和病理类型对其则均无明显影响。0．639、0．012和3．800,均P〉0．05）。结论^18F—FDGPET／CT多次显像有助于监测NSCLC术后复发和转移;术前肿瘤分期、原发灶大小及原发灶SUV。为2年内发生肿瘤复发和转移的影响因素。     

18F-FDG PET/CT显像在治疗后宫颈癌评估中的价值

目的 探讨18F-FDG PET/CT对临床怀疑宫颈癌局部复发和(或)远处转移患者的诊断价值.方法 回顾性分析95例宫颈癌治疗后患者的18F-FDG PET/CT检查资料,采用视觉分析和半定量方法(SUVmax)分析病灶特点,最终诊断以活组织病理检查、诊断性治疗及影像学随访结果为准,采用Kappa一致性检验进行分析.结果 共有54例患者18 F-FDG PET/CT检查发现局部复发和(或)远处转移病灶,其中局部复发24例,远处转移30例;18F-FDG PET/CT诊断肿瘤复发与转移的灵敏度、特异性和准确性分别为98.1％(52/53)、95.2％ (40/42)和96.8％ (92/95),阳性预测值与阴性预测值分别为96.3％ (52/54)和97.6％(40/41).18F-FDG PET/CT检查结果与病理及临床随访结果一致性良好(Kappa=0.936,P＜0.05).结论 18F-FDG PET/CT对临床可疑宫颈癌复发的诊断具有较高的灵敏度和特异性,有助于局部复发和(或)远处转移病灶的检测,对临床进一步的诊疗具有指导作用.     

18F-FDG PET/CT显像在非小细胞肺癌淋巴结转移及分期中的应用

目的 对比^18F—FDG PET／CT和CT评价非小细胞肺癌（NSCLC）患者淋巴结转移及分期（N分期）的价值。方法 回顾性分析68例行根治性手术治疗的NSCLC患者资料（术前同期行增强CT和^18F—FDG PET／CT检查，术中清扫各站淋巴结），根据其术后病理检查结果，结合影像学诊断，比较CT和PET／CT对肺癌淋巴结转移的诊断价值及确定N分期的准确性。结果 CT和PET／CT诊断纵隔淋巴结转移的灵敏度、特异性、准确性、阳性预测值（PPV）和阴性预测值（NPV）分别为63．6％，64．6％，64．3％，47．7％，77．8％与87．9％，87．7％，87．8％，78．4％，93．4％，差异均有统计学意义（P〈0．05）；CT与PET／CT诊断N分期的准确性分别为54．4％和76．5％，两者差异有统计学意义（P〈0．05）。结论 ^18F—FDG PET／CT在诊断NSCLC纵隔淋巴结转移方面的临床价值高于CT，能够更准确地确定N分期，指导治疗方案的选择。     

18F-FDGPET／CT诊断腹膜转移瘤的临床价值

目的评价18F-脱氧葡萄糖（FDG）PET／CT在腹膜转移瘤诊断中的临床价值。方法回顾性分析22例有原发恶性肿瘤手术史或不明原因腹腔积液而临床高度怀疑腹膜转移的患者资料。所有病例均行18F—FDGPET／CT检查,经病理检查或临床随访证实。结果22例中,有18例18F-FDGPET／CT诊断阳性,其中16例确诊腹膜转移,2例确诊为腹腔结核;4例PET／CT诊断阴性,其中3例确诊为腹膜炎性病变,1例确诊为腹膜转移瘤。18F—FDGPET／CT诊断腹膜转移瘤的灵敏度为94．1％（16／17）,特异性为3／5,阳性预测值为88．9％（16／18）,阴性预测值为3／4,准确性为86．4％（18／22）。结论在诊断腹膜转移瘤方面,18F—FDGPET／CT是一种可靠的、准确性较高的无创性检查,有重要的临床应用价值。     

18F-FDG PET/CT不同诊断方法对乳腺癌及其淋巴结转移的应用价值

目的 探讨18F-脱氧葡萄糖(FDG)PET/CT显像在诊断乳腺癌及其区域淋巴结转移中的临床价值.方法 对27例疑原发性乳腺癌及经临床随访(＞12个月)证实的12例单发乳腺良性病变患者行18F-FDG PET/CT显像,患者均为女性.对显像结果分别行定性、半定量分析.27例疑乳腺癌患者均行手术治疗.结果 疑乳腺癌患者术后病理检查示24例为乳腺癌,共25个病灶;良性病灶7个.18F-FDG PET/CT显像定性分析诊断乳腺癌的灵敏度为76.0%(19/25),特异性为94.7%(18/19);以最大标准摄取值(SUVmax)＞2.5为界值,18F-FDG PET/CT诊断乳腺癌的灵敏度为72.0%(18/25),特异性为63.2%(12/19);以病灶SUVmax大于对侧正常乳腺腺体SUVmax的-x+2s为界值,PET/CT诊断乳腺癌的灵敏度为96.0%(24/25),特异性为63.2%(12/19),其灵敏度明显高于前2种分析方法(X2=4.15,4.14;P均＜0.05).定性方法的特异性明显高于半定量分析(X2值均为5.7,P均＜0.05).23例行区域淋巴结廓清术的患者病理检查示10例有淋巴结转移.18F-FDGPET/CT定性诊断乳腺癌区域淋巴结转移的灵敏度为60.0%(6/10),特异性为84.6%(11/13);以SUVmax＞2.5为界值,18F-FDG PET/CT诊断淋巴结转移的灵敏度为60.0%(6/10),特异性为92.3%(12/13).结论 在18F-FDG PET/CT诊断乳腺癌中,以病灶SUVmax大于正常乳腺腺体sUVmax的-x+2s为界值的半定量分析有较好的灵敏度;定性分析的诊断特异性优于半定量分析.     

^18F-FDG PET／CT显像诊断妇科肿瘤复发、转移的价值

目的探讨^18F-脱氧葡萄糖（FDG）PET／CT显像诊断妇科肿瘤复发、转移的价值,并评价其对临床再分期及治疗决策的影响。方法对47例临床可疑复发、转移的妇科肿瘤患者行^18F—FDG PET／CT显像,对PET、CT及PET／CT图像进行对比分析。采用SPSS12．0软件,对数据行∥检验、校正的,检验及确切概率法分析。结果47例患者中共发现病灶158处,其中恶性病灶149处,良性病灶9处。^18F-FDG PET／CT诊断妇科肿瘤复发、转移的灵敏度、特异性、准确性、阳性预测值及阴性预测值分别为95．97％（143／149）,6／9,94．30％（149／158）,97．95％（143／146）及50．00％（6／12）。PET／CT在诊断妇科肿瘤复发、转移的灵敏度、准确性及阴性预测值方面明显优于单纯CT（χ^2=18．198,18．890,6．825,P均〈0．05）;^18F-FDG PET／CT和单纯PET在各项诊断效能指标间差异无统计学意义（χ^2=0．632,0．000,0．459,0．000,0．150,P均〉0．05）,但PET／CT使33．54％（53／158）的单纯PET无法准确定位的病灶得到了准确定位。同单纯CT及PET相比,PET／CT分别使44．68％（21／47）和31．91％（15／47）的患者TNM分期改变,对T分期的影响最明显;共有19．15％（9／47）的患者临床分期改变,并改变相应的治疗决策。结论^18F—FDG PET／CT显像诊断妇科肿瘤复发、转移准确而全面,对临床再分期及治疗决策有重要影响。